AnalystsInsight

Thomas Smith (Leerink Partners): Analyst Track Record and Price‑Target Accuracy

How often Thomas Smith’s price targets were reached, how fast, and what the stocks did after each call: a 7‑year backtest of 1,285 ratings, compared with the average Wall Street analyst.

3 min readHow we research

Key takeaways

  • Thomas Smith ranks #68 of 1,000 analysts in Exent’s scoring (5.0★).
  • 28.0% of price targets were reached over 7 years, versus 52.4% for the average analyst.
  • Median time to reach a target: 137 days; 48.2% of calls were up 12 months later.
  • Most‑covered stocks: VRDN, MDGL, IRON, ALMS.

Thomas Smith’s track record at a glance

Thomas Smith of Leerink Partners ranks #68 of the 1,000 analysts Exent scores, with a 5.0★ rating and a focus on healthcare. Over a 7‑year lookback, 28.0% of Thomas’s price targets were reached, 24.4 points below the 52.4% average across all analysts.

MetricThomas SmithAll analysts
Price‑target hit rate28.0%52.4%
Median days to hit target137 days91 days
Calls up after 12 months48.2%64.0%
Median 12‑month return of calls−2.5%+13.4%
Hit rate, last 2 years25.2%—
Average worst drop after a call−38.5%—
Ratings in the sample1,285—
Stocks covered36—

How fast price targets were reached

Time to reach the targetThomas Smith
Under 30 days16.5%
30–90 days19.8%
90–180 days26.5%
Over 180 days37.2%

Share of the targets that were reached, by how long they took. Targets are usually set for 12 months.

Stocks Thomas Smith covers most

StockRatings in the sample
VRDN29
MDGL25
IRON24
ALMS24
KROS23
ARGX23
RNAC23
VKTX23

In the past year Thomas’s ratings were 100% Buy, 0% Hold and 0% Sell.

Recent ratings (shown with a 30-day delay)

DateStockActionRatingPrice target
Sep 10, 2026IRONReiterated: BuyBuy$100.00
Sep 10, 2026SYRERated: BuyBuy$128.00
Sep 10, 2026EVMNRated: BuyBuy$22.00
Aug 4, 2026KROSReiterated: BuyBuy$23.00
Jul 28, 2026ALTReiterated: BuyBuy$10.00
Jul 24, 2026ARGXReiterated: BuyBuy$1065.00
Jul 22, 2026CLDXReiterated: BuyBuy$70.00
Jul 6, 2026AVTXInitiated Coverage: BuyBuy$38.00
Jun 22, 2026ALTInitiated Coverage: BuyBuy$10.00
Jun 12, 2026CLYMReiterated: BuyBuy$0.00
Jun 2, 2026XFORInitiated Coverage: BuyBuy$12.00
Jun 2, 2026XFORInitiated CoverageBuy$12.00
  • Sep 10, 2026
    Stock
    IRON
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $100.00
  • Sep 10, 2026
    Stock
    SYRE
    Action
    Rated: Buy
    Rating
    Buy
    Price target
    $128.00
  • Sep 10, 2026
    Stock
    EVMN
    Action
    Rated: Buy
    Rating
    Buy
    Price target
    $22.00
  • Aug 4, 2026
    Stock
    KROS
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $23.00
  • Jul 28, 2026
    Stock
    ALT
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $10.00
  • Jul 24, 2026
    Stock
    ARGX
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $1065.00
  • Jul 22, 2026
    Stock
    CLDX
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $70.00
  • Jul 6, 2026
    Stock
    AVTX
    Action
    Initiated Coverage: Buy
    Rating
    Buy
    Price target
    $38.00
  • Jun 22, 2026
    Stock
    ALT
    Action
    Initiated Coverage: Buy
    Rating
    Buy
    Price target
    $10.00
  • Jun 12, 2026
    Stock
    CLYM
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $0.00
  • Jun 2, 2026
    Stock
    XFOR
    Action
    Initiated Coverage: Buy
    Rating
    Buy
    Price target
    $12.00
  • Jun 2, 2026
    Stock
    XFOR
    Action
    Initiated Coverage
    Rating
    Buy
    Price target
    $12.00

Live ratings from Thomas Smith and the other top‑ranked analysts, and the stocks where they agree, are in Exent Stocks Radar.

How Exent scores analysts

Exent replays every rating with a price target over a 7‑year lookback: was the target reached, how long it took, and what the stock returned 1, 3, 6 and 12 months after the call. The star rating and rank combine success rate, average return and the number of ratings, so a few lucky calls do not make a top analyst. Statistics as of Jun 24, 2026; ranking updated Oct 16, 2026. How accurate are analyst price targets overall?

Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.

Follow the analysts with the best records

  1. Exent Stocks Radar shows Thomas Smith’s live ratings and those of the other top‑ranked analysts, without the 30‑day delay used on this page.
  2. Gems are the stocks where several 4★+ analysts agree: Exent’s shortlist of high‑conviction ideas.
  3. Check any idea against your own portfolio: correlation, concentration and crash exposure before you buy.

Exent is our product. Educational content, not investment advice.

Frequently asked questions

By Exent’s scoring Thomas Smith ranks #68 of 1,000 with a 5.0★ rating. 28.0% of price targets were reached over a 7-year lookback (all analysts: 52.4%), and 48.2% of calls were up 12 months later. Past accuracy does not guarantee future accuracy.

Thomas Smith’s success rate is 53.6% by the ranking source and 28.0% by Exent’s price-target hit-rate backtest, with a median of 137 days to reach a target.

Thomas Smith (Leerink Partners) covers 36 stocks, mostly in healthcare. The most frequently rated are VRDN, MDGL, IRON, ALMS, KROS.

Get the picks Wall Street’s best analysts agree on.

Exent tracks 4,000+ analysts, keeps only the elite few with proven records, and surfaces the Gems where they agree.

See this week’s GemsLimited offer$1.95 for full access· full access

Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.

DISCLAIMER: Exent AI is an informational research platform and does not provide investment advice, financial advice, or act as an investment adviser, broker-dealer, or fiduciary. All content, analytics, and model outputs are provided for educational and informational purposes only and should not be relied upon as a recommendation to buy, sell, or hold any financial instrument. Investing involves risk, including the possible loss of principal. Exent AI does not execute trades, hold customer funds, or provide brokerage services. Past performance and hypothetical results are not indicative of future results. Third-party data and AI-generated outputs may be incomplete or inaccurate.